Samarth Kulkarni Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Samarth Kulkarni.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Samarth Kulkarni. Samarth Kulkarni is Chief Business Officer in CRISPR Therapeutics AG ($CRSP) and Chief Executive Officer in CRISPR Therapeutics AG ($CRSP) and Please See Remarks in CRISPR Therapeutics AG ($CRSP) and Director in Black Diamond Therapeutics, Inc. ($BDTX) and Director in Repare Therapeutics Inc. ($RPTX).
Latest Insider Trading Transactions of Samarth Kulkarni
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, BDTX, CRSP, RPTX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 22 2021 | BDTX | Black Diamond Ther ... | Kulkarni Samarth | Director | Option Exercise | A | 12.55 | 15,000 | 188,250 | 15,000 | |
| Jun 17 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 12.57 | 30,000 | 377,100 | 63,333 | |
| Jun 17 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 127.51 | 3,488 | 444,755 | 187,719 | 191.2 K to 187.7 K (-1.82 %) |
| Jun 17 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 126.86 | 16,129 | 2,046,125 | 191,207 | 207.3 K to 191.2 K (-7.78 %) |
| Jun 17 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 125.39 | 10,383 | 1,301,924 | 207,336 | 217.7 K to 207.3 K (-4.77 %) |
| Jun 17 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 12.57 | 30,000 | 377,100 | 217,719 | 187.7 K to 217.7 K (+15.98 %) |
| May 14 2021 | RPTX | Repare Therapeutic ... | Kulkarni Samarth | Director | Option Exercise | A | 32.44 | 21,000 | 681,240 | 21,000 | |
| Apr 23 2021 | BDTX | Black Diamond Ther ... | Kulkarni Samarth | Director | Option Exercise | A | 24.33 | 14,921 | 363,028 | 14,921 | |
| Apr 23 2021 | BDTX | Black Diamond Ther ... | Kulkarni Samarth | Director | Option Exercise | A | 24.33 | 14,921 | 363,028 | 14,921 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 0.00 | 36,000 | 0 | 36,000 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 133.88 | 100,000 | 13,388,000 | 100,000 | |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 124.15 | 5,526 | 686,053 | 188,498 | 194 K to 188.5 K (-2.85 %) |
| Mar 12 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 0.00 | 11,833 | 0 | 194,024 | 182.2 K to 194 K (+6.49 %) |
| Mar 03 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 130.25 | 798 | 103,940 | 182,191 | 183 K to 182.2 K (-0.44 %) |
| Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 20,000 | 36,200 | 108,983 | |
| Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 217.44 | 1,304 | 283,542 | 182,989 | 184.3 K to 183 K (-0.71 %) |
| Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 216.50 | 1,708 | 369,782 | 184,293 | 186 K to 184.3 K (-0.92 %) |
| Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 214.68 | 1,700 | 364,956 | 186,001 | 187.7 K to 186 K (-0.91 %) |
| Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 213.71 | 5,623 | 1,201,691 | 187,701 | 193.3 K to 187.7 K (-2.91 %) |
| Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 212.75 | 6,525 | 1,388,194 | 193,324 | 199.8 K to 193.3 K (-3.26 %) |
| Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 211.83 | 3,140 | 665,146 | 199,849 | 203 K to 199.8 K (-1.55 %) |
| Jan 20 2021 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 20,000 | 36,200 | 202,989 | 183 K to 203 K (+10.93 %) |
| Dec 30 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 13,800 | 24,978 | 128,983 | |
| Dec 30 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 13,800 | 24,978 | 182,989 | 169.2 K to 183 K (+8.16 %) |
| Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 20,000 | 36,200 | 142,783 | |
| Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 144.97 | 600 | 86,982 | 169,189 | 169.8 K to 169.2 K (-0.35 %) |
| Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 143.71 | 2,100 | 301,791 | 169,789 | 171.9 K to 169.8 K (-1.22 %) |
| Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 142.75 | 6,766 | 965,847 | 171,889 | 178.7 K to 171.9 K (-3.79 %) |
| Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 141.98 | 5,034 | 714,727 | 178,655 | 183.7 K to 178.7 K (-2.74 %) |
| Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 141.17 | 5,500 | 776,435 | 183,689 | 189.2 K to 183.7 K (-2.91 %) |
| Dec 11 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 20,000 | 36,200 | 189,189 | 169.2 K to 189.2 K (+11.82 %) |
| Dec 03 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 129.58 | 779 | 100,943 | 169,189 | 170 K to 169.2 K (-0.46 %) |
| Oct 06 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 86.75 | 47,333 | 4,106,138 | 47,333 | |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 94.15 | 779 | 73,343 | 169,968 | 170.7 K to 170 K (-0.46 %) |
| Sep 03 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 94.15 | 779 | 73,343 | 169,968 | 170.7 K to 170 K (-0.46 %) |
| Jun 03 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 17,275 | 31,268 | 162,783 | |
| Jun 03 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 66.26 | 779 | 51,617 | 170,747 | 171.5 K to 170.7 K (-0.45 %) |
| Jun 03 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 65.26 | 5,575 | 363,825 | 171,526 | 177.1 K to 171.5 K (-3.15 %) |
| Jun 03 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 64.61 | 9,300 | 600,873 | 177,101 | 186.4 K to 177.1 K (-4.99 %) |
| Jun 03 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 63.57 | 2,400 | 152,568 | 186,401 | 188.8 K to 186.4 K (-1.27 %) |
| Jun 03 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 17,275 | 31,268 | 188,801 | 171.5 K to 188.8 K (+10.07 %) |
| May 21 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 10,693 | 19,354 | 180,058 | |
| May 21 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 4,307 | 7,796 | 190,751 | |
| May 21 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 65.28 | 10,693 | 698,039 | 171,526 | 182.2 K to 171.5 K (-5.87 %) |
| May 21 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 10,693 | 19,354 | 182,219 | 171.5 K to 182.2 K (+6.23 %) |
| May 21 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 65.16 | 4,307 | 280,644 | 171,526 | 175.8 K to 171.5 K (-2.45 %) |
| May 21 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 4,307 | 7,796 | 175,833 | 171.5 K to 175.8 K (+2.51 %) |
| Mar 04 2020 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 52.74 | 794 | 41,876 | 171,526 | 172.3 K to 171.5 K (-0.46 %) |
| Dec 18 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 8,000 | 14,480 | 195,058 | |
| Dec 18 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 8,000 | 14,480 | 172,320 | 164.3 K to 172.3 K (+4.87 %) |
| Dec 05 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 0.00 | 120,000 | 0 | 120,000 | |
| Dec 02 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 71.65 | 741 | 53,093 | 164,320 | 165.1 K to 164.3 K (-0.45 %) |
| Sep 03 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 46.21 | 740 | 34,195 | 165,061 | 165.8 K to 165.1 K (-0.45 %) |
| Jun 19 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 20,000 | 36,200 | 203,058 | |
| Jun 19 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 46.00 | 20,000 | 920,000 | 165,801 | 185.8 K to 165.8 K (-10.76 %) |
| Jun 19 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 20,000 | 36,200 | 185,801 | 165.8 K to 185.8 K (+12.06 %) |
| Jun 04 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 35.57 | 741 | 26,357 | 165,801 | 166.5 K to 165.8 K (-0.44 %) |
| May 01 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 20,000 | 36,200 | 223,058 | |
| May 01 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 42.03 | 20,000 | 840,600 | 166,542 | 186.5 K to 166.5 K (-10.72 %) |
| May 01 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 20,000 | 36,200 | 186,542 | 166.5 K to 186.5 K (+12.01 %) |
| Mar 07 2019 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 40.87 | 250,000 | 10,217,500 | 250,000 | |
| Dec 11 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 21,500 | 38,915 | 243,058 | |
| Dec 11 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 21,500 | 38,915 | 167,290 | 145.8 K to 167.3 K (+14.75 %) |
| Dec 03 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 38.33 | 741 | 28,403 | 145,790 | 146.5 K to 145.8 K (-0.51 %) |
| Sep 04 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 56.67 | 741 | 41,992 | 146,531 | 147.3 K to 146.5 K (-0.50 %) |
| Jun 15 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 59.31 | 109,000 | 6,464,790 | 109,000 | |
| Jun 15 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 59.31 | 109,000 | 6,464,790 | 109,000 | |
| Jun 05 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 15,000 | 27,150 | 264,558 | |
| Jun 05 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Payment of Exercise | F | 67.13 | 741 | 49,743 | 147,819 | 148.6 K to 147.8 K (-0.50 %) |
| Jun 05 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 70.28 | 10,400 | 730,912 | 148,560 | 159 K to 148.6 K (-6.54 %) |
| Jun 05 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Sell | S | 67.28 | 4,600 | 309,488 | 158,960 | 163.6 K to 159 K (-2.81 %) |
| Jun 05 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 15,000 | 27,150 | 163,560 | 148.6 K to 163.6 K (+10.10 %) |
| Apr 18 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 19.12 | 75,000 | 1,434,000 | 150,000 | |
| Apr 18 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 19.12 | 75,000 | 1,434,000 | 150,000 | |
| Mar 14 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 19.12 | 75,000 | 1,434,000 | 75,000 | |
| Mar 09 2018 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 51.49 | 136,000 | 7,002,640 | 136,000 | |
| Dec 26 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | M | 1.81 | 15,000 | 27,150 | 279,558 | |
| Dec 26 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Buy | M | 1.81 | 15,000 | 27,150 | 148,560 | 133.6 K to 148.6 K (+11.23 %) |
| Dec 05 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Option Exercise | A | 19.12 | 260,000 | 4,971,200 | 260,000 | |
| Dec 05 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Executive Off ... | Grant | A | 19.12 | 26,667 | 509,873 | 133,560 | 106.9 K to 133.6 K (+24.95 %) |
| Aug 30 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 20.00 | 4,000 | 80,000 | 106,893 | 110.9 K to 106.9 K (-3.61 %) |
| Aug 30 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 20.09 | 23,154 | 465,162 | 110,893 | 134 K to 110.9 K (-17.27 %) |
| May 05 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Please See Remarks | Option Exercise | A | 16.21 | 100,000 | 1,621,000 | 100,000 | |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 2,206 | 3,993 | 294,558 | |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 3,275 | 5,928 | 296,764 | |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 16.78 | 2,206 | 37,023 | 134,047 | 136.3 K to 134 K (-1.62 %) |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 2,206 | 3,993 | 136,253 | 134 K to 136.3 K (+1.65 %) |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 16.74 | 3,275 | 54,816 | 134,047 | 137.3 K to 134 K (-2.38 %) |
| Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 3,275 | 5,928 | 137,322 | 134 K to 137.3 K (+2.44 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 5,115 | 9,258 | 300,039 | |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 3,500 | 6,335 | 305,154 | |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 3,000 | 5,430 | 308,654 | |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 16.87 | 5,115 | 86,290 | 134,047 | 139.2 K to 134 K (-3.68 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 5,115 | 9,258 | 139,162 | 134 K to 139.2 K (+3.82 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 16.46 | 3,500 | 57,619 | 134,047 | 137.5 K to 134 K (-2.54 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 3,500 | 6,335 | 137,547 | 134 K to 137.5 K (+2.61 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 17.01 | 3,000 | 51,033 | 134,047 | 137 K to 134 K (-2.19 %) |
| Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 3,000 | 5,430 | 137,047 | 134 K to 137 K (+2.24 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 2,800 | 5,068 | 311,654 | |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Option Exercise | M | 1.81 | 7,258 | 13,137 | 314,454 | |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 17.36 | 2,800 | 48,621 | 134,047 | 136.8 K to 134 K (-2.05 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 2,800 | 5,068 | 136,847 | 134 K to 136.8 K (+2.09 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 18.54 | 2,449 | 45,393 | 134,047 | 136.5 K to 134 K (-1.79 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Sell | S | 17.54 | 4,809 | 84,361 | 136,496 | 141.3 K to 136.5 K (-3.40 %) |
| Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Kulkarni Samarth | Chief Business Offi ... | Buy | M | 1.81 | 7,258 | 13,137 | 141,305 | 134 K to 141.3 K (+5.41 %) |
Page: 1